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Abstract: The purpose of this study was to develop a model 
system for targeted drug delivery. This system should ena-
ble targeted drug release at a certain tissue in the body. 
In conventional drug delivery systems, drugs are often 
delivered unspecifically resulting in unwarranted adverse 
effects. To circumvent this problem, there is an increasing 
demand for the development of intelligent drug delivery 
systems allowing a tissue-specific mode of delivery. Within 
this study, nanoparticles consisting of two biocompatible 
polymers are used. Because of their small size, nanopar-
ticles are well-suited for effective drug delivery. The small 
size affects their movement through cell and tissue bar-
riers. Their cellular uptake is easier when compared to 
larger drug delivery systems. Paclitaxel was encapsulated 
into the nanoparticles as a model drug, and to achieve 
specific targeting an aptamer directed against lung can-
cer cells was coupled to the nanoparticles surface. Nano-
particles were characterized by dynamic light scattering 
(DLS), transmission electron microscopy (TEM), fourier 
transform infrared spectroscopy (FTIR), and nanotrack-
ing analysis (NTA). Also their surface charge was charac-
terized from ζ-potential measurements. Their preparation 
was optimized and subsequently specificity of drug-
loaded and aptamer-functionalized nanoparticles was 
investigated using lung cancer cells.
Keywords: aptamer; HOOC-PEG-PCL; mPEG-PCL; 
nanoparticles.
Introduction
Today many therapeutics have poor pharmacokinetic and 
biopharmaceutical properties which hamper their applica-
tion in long-term therapy [1–4]. This is due to the systemic 
application of those drugs. Especially chemotherapeutics 
exert consequently unspecific toxic side effects on non-tar-
get tissues [5]. To solve these problems, many drug delivery 
systems like micelles, vesicles or nanospheres are available 
[4, 6]. These systems are designed for transporting a phar-
maceutical compound in the body (Jain PharmaBiotech, 
Basel, 2008). Currently, they have several limitations like 
non-specific drug delivery [7]. Furthermore, most of these 
systems cannot penetrate the cell membrane to induce 
cytotoxicity. In this context, targeted drug delivery systems 
are a very promising alternative, as they allow for specific 
delivery as well as efficient intracellularization.
Targeted drug delivery is a preferred method for drug 
administration that increases the concentration of the 
drug at the desired sites of action, while leaving other 
tissues of the body unaffected [4]. This kind of release is 
one special focus of nanomedicine [4, 8]. Because of their 
small sizes, nanoparticles are able to penetrate inflam-
matory sites, tumors or microcapillaries [9]. They are also 
able to cross the blood-brain barrier unlike other drug 
delivery systems with bigger sizes [9]. The small size also 
allows a high cellular uptake by a variety of cell types [9, 
10]. Regarding drug release nanosized drug carrier have 
a larger surface area-to-volume ratio meaning that they 
have a greater efficiency regarding drug delivery [9, 11].
In one common design of drug delivery systems, 
nanoparticles are loaded with drugs and specificity is 
achieved by conjugation with a ligand that solely binds 
to diseased cells. Interactions with healthy tissue should 
be hampered [12]. Consequently, the advantages of a tar-
geted drug delivery system are reduction of adverse effects 
in combination with increased efficacy [13, 14]. In con-
ventional drug delivery systems lacking specific ligands, 
the drug diffuses in the whole body by systemic blood 
circulation without any specific mechanism facilitating 
accumulation at the desired site of action. Under most 
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circumstances only a small proportion of therapeutics 
reaches the target organ [7, 15].
A targeted drug delivery system has to be constructed 
in the following way: the carrier material needs to be bio-
compatible and biodegradable [6]. The material could 
be biological such as lipids, lactic acid or chitosan, or it 
could be chemical such as titan dioxide or cadmium [6]. 
In this study, methoxypolyethylene glycol (mPEG-PCL) 
and R-carboxyl polyethylene glycol (HOOC-PEG-PCL) were 
used, which are FDA approved biocompatible polymers. 
PEG-PCL is nontoxic and an amphiphilic copolymer [16, 
17]. PEG polymers have a high colloidal stability and a 
resistance against protein adsorption so non-specific 
nanoparticle interactions with cell membranes are pre-
vented [18]. A high stability of the used carrier material 
is necessary for increasing efficiency of drug by prolonga-
tion of nanoparticles residence time in the circulation [9]. 
For that reason, two compounds containing PEG moieties 
were used in this study. Nanoparticles were prepared by 
using solvent evaporation method [19]. Gao et  al. have 
developed a targeted drug delivery system which consists 
of mPEG-PCL, HOOC-PEG-PCL and maleimide-PEG-PCL 
(MAL-PEG-PCL) and is functionalized with an aptamer 
(AS11411) and a 12-amino acid peptide. The AS111411 
aptamer binds to necleolin, which is a highly expressed 
protein in the plasma membrane of cancer cells like 
glioma cells. The TGN peptide is selected by an in vivo 
phage display screening and allows modified nanopar-
ticles the easier penetration of the blood brain barrier 
compared with the native phage [19]. In this study we are 
transferring this system to two other aptamers which are 
specific for lung cancer cells and load the drug delivery 
system with the anticancer drug paclitaxel.
The drug can either be encapsulated in the hydropho-
bic core of the carrier or coupled to its surface depending 
on the drugs’ lipophilicity [9]. In this study, paclitaxel 
(PTX/Taxol) was used. PTX was originally isolated from 
pacific yew bark and belongs to the group of taxanes. 
It exhibits an anti-neoplastic activity against various 
types of tumors [16] qualifying PTX for the therapy of 
lung cancer. PTX operates as inhibitor of cell mitosis by 
binding to β-tubulin and disturbing the degradation of 
microtubules [20].
In order to achieve specific delivery at the desired site 
of action, the surface of the particles has to be modified 
with a targeting molecule [12]. This could be an aptamer, 
antibody, peptide or protein [21, 22]. Based on their high 
affinity and specificity, aptamers can be used as targeting 
ligands in a broad range of applications including affin-
ity separation, analytics and cell targeting [23]. Aptam-
ers are short single-stranded or double-stranded RNA/
DNA molecules which are able to detect cell-specific 
molecules like receptors present on the cell surface with 
a high selectivity. In comparison to antibodies, aptam-
ers have a high stability, a straight forward modification 
potential and lack of immunogenicity [24, 25]. Aptamers 
are recovered by a procedure named SELEX (Systematic 
Evolution of Ligands by Exponential Enrichment) [26]. 
This procedure selects those oligonucleotides which are 
binding the desired target with the highest affinity [26, 
27]. The mentioned characteristics encouraged us to use 
the aptamers S15 and S6 which specifically bind to lung 
cancer cells as a ligand for the model targeted drug deliv-
ery system [25].
To evaluate the cytotoxicity of the developed system 
the lung cancer cell line A549 and the cervix cancer cell 
line HeLa were used. While A549 cells are the target cells, 
against which the used aptamers have been selected, a 
limited affinity of the aptamers has also been reported 
against HeLa cells. This cross-reactivity is most likely 
based on a molecular target that is present on the surface 
of both cell lines.
The aim of this study was to develop a model system 
for targeted drug delivery, optimizing its preparation and 
investigating the cytotoxicity as well as the specificity 
of the system. The nanoparticles were characterized by 
dynamic light scattering (DLS) in terms of their hydro-
dynamic diameter, their surface charge by measuring 
the ζ-potential and by transmission electron microscopy 
(TEM) in terms of their morphology. The functionaliza-
tion with aptamers was confirmed by agarose gel electro-
phoresis. PTX encapsulation efficiency was determined 
by HPLC. In order to demonstrate the applicability of the 
developed system in targeted drug delivery, cytotoxicity 
tests were performed.
Results and discussion
The aim of this study was to develop a model system for 
targeted drug delivery, optimizing it and investigating 
the cytotoxicity as well as the specificity of the system. 
Therefore, first corresponding copolymers mPEG-PCL and 
HOOC-PEG-PCL were prepared which than were used to 
produce the PEG-PCL nanoparticles. PTX was encapsu-
lated during the preparation procedure and afterwards 
NPs were functionalized with S6 and S15 aptamers. In the 
following, NPs are named according to their composition: 
PEG-PCL-S15 (PTX) and PEG-PCL-S6 (PTX) for aptamer-
modified NPs containing PTX, and PEG-PCL-S15 and PEG-
PCL-S6 for NPs without PTX.
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Preparation of copolymers
First the copolymers were prepared by a ringopening 
copolymerization of mPEG and ε-caprolactone as the 
first compound and HOOC-PEG and ε-caprolactone as the 
second compound. The success of the copolymerization of 
the two compounds was determined by 1H NMR. Figure 1 
demonstrates the result of the copolymerization of HOOC-
PEG-PCL. The peak of PEG protons was at δ3.7 ppm and 
that one of the PCL protons at δ2.3 ppm. The peak at of 
solvent protons is at δ7.2 ppm. The results were in accord-
ance to those reported before by Gao et al. and thus con-
firmed successfully [19].
Figure 2 shows the FTIR spectra of HOOC-PEG-
PCL and mPEG-PCL. In the spectrum of HOOC-PEG-PCL 
(Figure 2), the sharp and intense bands at 1724 cm−1 and 
1376  cm−1 were attributed to the presence of carboxylic 
ester (C = O) and ether (C–O) groups. The same result 
is shown in Figure 2. The sharp and intense bands at 
1727 cm−1 and 1347 cm−1 were attributed to the presence of 
carboxylic ester and ether groups. This indicates that the 
formation of both copolymers was successfully.
Optimizing preparation
Particles were prepared using the solvent evaporation 
method. The two compounds mPEG-PCL and HOOC-PEG-
PCL were dissolved in DCM and then dropwise added to a 
stirred sodium cholate hydrate solution. To optimize the 
preparation procedure, the stirring rate was modified and 
the resulting nanoparticles were characterized by DLS. 
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Figure 1: 1H NMR o HOOC-PEG-PCL.
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Figure 2: FTIR of HOOC-PEG-PCL and mPEG-PCL.
Different stirring rates as well as combinations of differ-
ent stirring rates were tested in order to achieve nanopar-
ticles with a narrow size distribution. Best results were 
achieved by a sequence of strong stirring rate (750 rpm, 
1 h) followed by gentle stirring (350 rpm, 3 h; Figure 3A). 
Using a continuously strong or continuously gentle stir-
ring rate, only an irregular size distribution of the hydro-
dynamic diameter could be observed. Obviously, a strong 
or ongoing gentle stirring rate hamper the compounds to 
form uniform particles. In case of the gentle stirring rate, 
the copolymer formed huge particles of irregular size dis-
tribution. The hydrodynamic diameter of the particles 
was reproducible found to be in the range of 100–200 nm 
which was consistent with the characterization of the 
hydrodynamic diameter with NTA resulting in a diameter 
of 130–150 nm.
Next the time of sonication was modified (Figure 
3B). Ultra-sonication is necessary to get small particles 
and break larger agglomerates. Using an ultra-sonication 
time of 120 s and 75 s a spacious size distribution of the 
hydrodynamic diameter was observed (Figure 3B). The 
optimal duration of ultra-sonication was at 90 s. Leading 
to a small size distribution indicated by a defined peak 
(see arrow, Figure 3B) at 170–200 nm. In contrast, sonifi-
cation enduring 75 s or 120 s revealed NPs with a broader 
size distribution. Thus, a sonication time of 90 s was used 
for all subsequent experiments. A possible reason for the 
broader size distribution observed after sonication for 75 s 
could be, that the sample is still containing some agglom-
erates which did not break during short sonication.
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In order to remove free copolymer that has not been 
incorporated into nanoparticles, overnight dialysis was 
performed. After dialysis with 3.5 kDa and 6 kDa DLS anal-
ysis revealed the absence of the peak of the hydrodynamic 
diameter at approximately 25 nm, which was present in 
Figure 3A and B before dialysis. Possibly this could be 
that 25 nm peak corresponds to monomers remaining in 
the solution after particle formation. The monomers are 
able to pass the dialysis membrane at a cut-off of 3.5 kDa 
(Figure 4).
Characterizing the particles
The morphology of the particles was characterized by 
TEM. In Figure 5 spherical shaped particles are seen. The 
small size of 3 nm of the particles could be explained by 
the drying of the sample before TEM analysis. This results 
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Figure 3: Hydrodynamic diameter of the particles produced with using different stirring rates (A) and variations of ultra-sonication rates (B) 
characterized by DLS. There is a small peak at 25 nm and the maximum at 150–170 nm.
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Figure 4: Different cut-offs during the dialysis after 350 rpm 1 h and 
750 rpm 2 h and an ultra-sonication for 90 s.
Figure 5: TEM analysis of the nanoparticles.
in a shrinking of the PEG shell of the particles. This obser-
vation has already been described in literature [28–30].
After determining the morphology of the particles 
their concentration was characterized. Nanoparticles’ 
concentration was checked by lyophilisation and was 
reproducible at 2.8 mg/mL.
After determining the morphology and concentra-
tion of the particles their surface charge was character-
ized from ζ-potential measurements. Figure 6 shows the 
ζ-potential of the nanoparticles.
NPs without drug loading and functionalization 
have a ζ-potential at –21 mV. Drug loaded NPs have a 
higher positive ζ-potential of –18 mV. This observation 
is in accordance with the literature [31]. NPs functional-
ized with aptamers without drug loading have a higher 
negative surface charge (between –30  mV and –32 mV) 
than NPs without modification and drug loading. This 
is an anticipated result because aptamers are negatively 
charged and further confirms the successful modification 
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of NPs with aptamers. NPs functionalized with the S6 
aptamer generally have a lower ζ-potential (–32 mV and 
–30 mV with PTX). A possible reason could be a different 
folding of the two aptamers resulting in differences of the 
charge distribution on the NP surface.
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Figure 6: Zeta potential of the nanoparticles. NPs, nanoparticles; 
NPPTX, nanoparticles loaded with PTX; NPS6, nanoparticles func-
tionalized with S6 aptamer; NPS15, nanoparticles functionalized 
with S15 aptamer; NPPTXS6, nanoparticles loaded with PTX and 
functionalized with S6 aptamer; NPPTXS15, nanoparticles loaded 
with PTX and functionalized with S15 aptamer.
NP Np+S15 S15 W1 W2 W3 W4 W5 W6 W7 W8 gel.P.
NP Np+S6 S6 W1 W2 W3 W4 W5 W6 W7 W8 gel.P.
Figure 7: Top: Agarosegel of PEG-PCL-S15. NP, nanoparticles before conjugation; S15, aptamer directed against lung cancer cells; W1-W8, 
washing fractions, cut-off:100 kDa; gel.P., purified conjugate. Bottom: Agarosegel of PEG-PCL-S6. NP, nanoparticles before conjugtion; S6, 
aptamer directed against lung cancer cells; W1-W8, washing fractions, cut-off:100 kDa; gel.P., purified conjugate.
Functionalization
For a targeted drug delivery system, the drug carrier is 
modified with a targeting ligand. Aptamers are able to 
detect cell-specific receptors and molecules so in this 
study S15 and S6 aptamers were used which are directed 
against the lung cancer cell line A549. Aptamers were 
coupled via an EDC-coupling on the nanoparticles’ 
surface. To remove the uncoupled aptamers, excessive 
buffer exchange was performed using centrifugal concen-
trators (100 kDa MWCO). Figure 7 shows the results of the 
functionalization with both aptamers.
While some unbound aptamer was found in the first 
washing fraction, in the following washing fractions no 
aptamer was detected. For the purified conjugates, a band 
corresponding to the aptamer was found. This indicates 
that most of the aptamer was bound to the nanoparticles 
and that free aptamer was successfully removed.
Hydrodynamic diameter of aptamer-conjugated nan-
oparticles was determined via DLS analysis (Figure 8). 
Nanoparticles with aptamer have a bigger size distribu-
tion of the hydrodynamic diameter than particles without 
aptamer. Here one has to consider that the modification of 
the nanoparticles with aptamers influences the hydrody-
namic size of the particle via two contrary mechanisms: 
First, the size of the particle increases due to the presence 
of relatively large aptamers. On the other hand, aptamers 
are ssDNAs/RNAs oligonucleotides exhibiting a negative 
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charge. The negative charge of the aptamer-modified par-
ticles results in a stronger attraction of the hydration shell 
and thus in smaller hydrodynamic diameters. Moreover, 
the hydrodynamic diameter may also be affected by the 
folding of the aptamer depending on the aptamer density: 
At low aptamer densities, the aptamer may be more flex-
ible than at higher aptamer densities for which the elec-
trostatic repulsion of negatively charged aptamers results 
in a straightening of the aptamers [32]. In summary our 
results suggest successful conjugation with aptamer-
conjugated nanoparticles with a hydrodynamic diameter 
between 100 nm and 300 nm and a maximum at 160 nm.
Encapsulation of PTX
PTX was encapsulated during the dissolution of the two 
compounds of the particles in DCM [16, 19]. After dissolv-
ing all three compounds, the solution was dropwise added 
to sodium cholate hydrate solution. When an amount of 
200 μg/mL PTX was used during particle formation, the 
encapsulation efficiency was nearly 44% and 43.89 μg/
mL of PTX were encapsulated. So the maximum amount 
of PTX which could reach the cells is about 7.3 ng per cell. 
Particles loaded with PTX were used for further investiga-
tion of cytotoxicity.
Incubation of cells with drug loaded and 
functionalized NPs
Nanoparticles (2.8 mg/mL) loaded with 200 μg/mL PTX 
[16] were incubated with A549 cells.
We have recently used aptamer S15-functionalized 
quantum dots for specific staining of A549 cells [33]. We 
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Figure 8: Nanoparticles with and without aptamer; characterized 
by DLS.
also have compared the binding of S15 to A549 cells in 
comparison to a random oligonucleotide as a negative 
control. So we could demonstrate that S15 is specific for 
A549 cells [18]. According to propidium iodide staining in 
Figure 9A, A549 cells incubated with PEG-PCL-S15 (PTX) 
particles died Calcein-AM staining revealed absence of 
living cells under these conditions. In contrast, the control 
(HeLa cells, Figure 9C) showed no dead cells. Although a 
certain affinity of aptamer S15 has been described in the 
literature, the binding to HeLa was reported to be weak 
when compared to aptamer binding to A549 cells [25]. 
Therefore, our results demonstrate the higher specificity 
of the conjugates to A549 cells.
The sample with S6 aptamer (PEG-PCL-S6) showed 
no dead cells for both, A549 cells and HeLa cells. A pos-
sible reason could be that S6 is binding to different recep-
tors of A549 cells that do not trigger the endocytosis. In 
another set of experiments, drug-loaded nanoparticles 
not functionalized with aptamers (PEG-PCL (PTX)) were 
used as a negative control resulting in no increase of dead 
cells (data not shown). A549 and HeLa did not die as well 
after incubation with PEG-PCL-S15 and PEG-PCL-S6 (data 
not shown). Therefore, the specific targeting and cellu-
lar uptake was demonstrated for S15-modified particles, 
whereas S6-conjugated particles failed in penetration of 
the cell membrane.
Cells incubated with unloaded NPs or with NPs not 
functionalized with an aptamer did not die, meaning 
that the composition of NPs is not toxic for the cells 
(Figure 9E). Cells incubated with pure taxol died (up to 
50%) after the incubation time of 24 h (data not shown).
Conclusion and further experiments
The aim of the study was to develop a model system for 
targeted drug delivery and its optimization. Nanoparticles 
could be produced successfully and the production was 
optimized. Furthermore their hydrodynamic diameter was 
characterized and also their morphology. PTX was encap-
sulated successfully with an efficiency of 44%. Finally, 
functionalization with two different targeting ligands was 
confirmed.
To investigate the cytotoxicity and specificity of the 
developed drug delivery system A549 and HeLa cells were 
incubated with drug-loaded and aptamer-functionalized 
NPs, drug loaded NPs and only NPs (PEG-PCL-S15 (PTX), 
PEG-PCL-S15, PEG-PCL-S6 (PTX), and PEG-PCL-S6). The 
results demonstrated specific delivery and cellular uptake 
into A549 cells for S15-modified NPs. S6-modified particles 
were not able to deliver the incorporated drug into A549 
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cells most likely because the aptamers molecular target 
does not facilitate endocytosis. In future work we will 
further optimize aptamer density and investigate the cyto-
toxicity of different drugs and drug concentrations. We 
also will investigate interactions between NPs and cells by 
incorporation of fluorescent dyes to the NPs and analysis 
of cellular binding and uptake of these NPs via confocal 
microscopy. Finally cytotoxicity tests with other cancer 
cells and healthy cells (esp. liver cells) will be performed.
Materials and methods
Materials
Monomethoxy-polyethylene glycol (mPEG, MW = 5000 Da), R-car-
boxyl polyethylene glycol (HOOC-PEG, MW = 114.14 Da), Coumarin-6, 
N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
(EDC), sodium cholate hydrate, boric acid (99%), paclitaxel (PTX) 
and Dulbecco’s Modified Eagle’s Medium (DMEM) were purchased 
A B
C D
E F
Figure 9: Staining with Calcein-AM/propidium iodide A: A549 cells were incubated with PEG-PCL-S15 (PTX) for 24 h; B: A549 cells were 
incubated with PEG-PCL-S6 (PTX) for 24 h; C: HeLa cells were incubated with PEG-PCL-S15 (PTX) for 24 h; D: HeLa cells were incubated with 
PEG-PCL-S6 (PTX) for 24 h. E: A549 cells were incubated with PEG-PCL particles. F: HeLa cells were incubated with PEG-PCL particles.
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from Sigma Aldrich (Germany). A549 cell line (lung cancer) and HeLa 
(human cervix cancer) cells were acquired from ‘Deutsche Sammlung 
von Mikroorganismen und Zellkulturen GmbH (DMSZ). Supplements 
for the cell culture medium DMEM and fetal bovine serum (FKS) were 
purchased from PAA Laboratories GmbH, and penicillin/streptomy-
cin (P/S) was purchased from Biochrom GmbH, Germany.
The S15 aptamer has the following sequence and a 5′ amino-
C6 linker: GCTATCTTATGG AAATTTCGTGTAGGGTTTGGTGTG-
GCGGGGCTA. The S6 aptamer has the following sequence and a 5′ 
amino-C6 linker: GTGGCCAGTCACTCAATTGGG TGTAGGGG TGGG-
GATTGTGGGTTG [25]. Both S15 and S6 aptamers were purchased from 
BioSpring Gesellschaft für Biotechnologie mbH, Frankfurt/Main.
Agarose was purchased from Carl Roth GmbH, Karlsruhe, 
TAE-buffer for the agarose gel electrophoresis consists of 2-Amino-
2-(hydroxylmehtyl)-1,3-propandiole (TRIS-Base) which was also 
purchased from Sigma Aldrich GmbH (Germany), glacial acetic acid 
which was acquired from AppliChem GmbH, Darmstadt and EDTA 
(Ethylenediaminetetraacetate) which was purchased from Sigma 
Aldrich GmbH (Germany). Roti-Safe Gelstain was also purchased 
from Carl Roth GmbH, Karlsruhe.
Synthesis and characterization of copolymers
Methoxy polyethylene glycol (mPEG) was dehydrated by an azeo-
tropic distillation in toluene (30 mL) and then dried by vacuum at 
50 °C. ε-Caprolactone was dried under vacuum for 24 h. 5 g of the 
ε-Caprolactone, 5 g of the mPEG and the catalyst stannous octoate 
(0.1%) are added into a 50 mL dried glass reactor and the ringopen-
ing copolymerization was carried out at 130 °C for 24 h under reduced 
pressure (stirred slowly). The reaction was terminated by cooling in 
water [19]. HOOC-PEG-PCL was synthesized identically. The suc-
cess of the copolymerization was characterized by 1H NMR (Varian 
VNMRS 400; 400 MHz, CDCl3) and FTIR (IFS 66 BRUKER, equipped 
with an internal reflection element 45° ZnSe crystal and a deuterated 
triglycine sulfate (DTGS) detector).
Preparation of nanoparticles
The nanoparticles (NPs) were synthesized by a solvent evaporation 
method. 28  mg of mPEG-PCL and 3  mg HOOC-PEG-PCL were dis-
solved in 1 mL of dichloromethane (DCM) and then dropwise added 
to 5 mL of a 0.6% sodium cholate hydrate solution. For the encapsu-
lation of PTX, different amounts of PTX (200 μg/mL) were added to 
the mPEG-PCL-DCM solution.
The solution was stirred for 1 h at 750 rpm and for 2 h at 350 rpm 
and then pulse sonicated for 90  s 200 W. Stirring rate and ultra-
sonication rate were varied in case of optimization of nanoparticles’ 
preparation. Then the mixture was applied to a rotary evaporator to 
remove DCM. To remove unreacted monomers and PTX which was 
not encapsulated, a dialysis was performed with cut-offs of 3.5 kDa 
and 6 kDa.
For the functionalization with the S15 and S6 aptamers the car-
boxylated PEG of the nanoparticle was activated by EDC. Therefore, 
the aptamer (177 μM, 16 μL) was added to NP solution (2.8 mg/mL, 
24.4 μL) in sodium borate buffer (SBB; 10 mM, pH 7.4). After mix-
ing  the solution on a rotary mixer (labtech) for 5 min, 6.5 μL of a 
10  mg/mL EDC-solution were added and then incubated for 3  h at 
room temperature on the rotary mixer. Afterwards the conjugates 
were purified using centrifugal concentrators (Vivaspin®, 100  kDa 
cut-off). This process was used to remove unreacted aptamers; suc-
cess was checked by agarose gel electrophoresis (1.2%, 100 V, stained 
with 5 μL/100 mL agarose gel Roti-Safe Gel-Stain).
Characterization of NPs
Particle size was determined by dynamic light scattering (DLS, Mal-
vern Instruments Ltd., zetasizer Nano ZS, UK). The surface charge of 
the NPs was determined from ζ-potential measurements (Malvern 
Instruments Ltd., zetasizer Nano ZS, UK). The exactly number of par-
ticles per mL was measured by nanotracking analysis (NTA, Malvern 
Instruments Ltd., zetasizer Nano ZS, UK). Morphology was character-
ized by transmission electron microscopy (TEM, FEI Tecnai G2 F20 
TMP-TEM with a 200 kV FEG (field emission gun)). Samples were pre-
pared by placing a droplet on a carbon coated mesh copper grid and 
then they were dried with air. For determination of the concentration 
of the particles a lyophilization (Eppendorf concentrator 5301) was 
done.
Encapsulation efficiency of PTX in nanoparticles
The encapsulation efficiency was determined by high performance 
liquid chromatography (HPLC, VWR Hitachi Chromaster). The mobile 
phase consisted of acetonitrile/water (50:50 v/v). Column (Kinetex 
C18, 2.6 μm, 100 A, 100 × 4.6 mm) temperature was at 25 °C and the 
flow rate was set at 1 mL/min; detection wavelength was 225 nm. 
Sample solution was injected at a volume of 10 μL. The calibration 
was done with standard solutions of PTX (5–1000 μg/mL) dissolved 
in water. Analyzing the encapsulation efficiency of the PTX was per-
formed using the calibration data with the Agilent series OpenLAB 
Control Panel software. To calculate the encapsulation efficiency fol-
lowing formula was used [16]:
amount of PTX in nanoparticlesencapsulation efficiency [%] 100
initial amount of PTX
= ×
Optimizing of NP preparation
The NP preparation was optimized with regard to size distribution. 
Therefore, stirring rate and ultra-sonication rate were varied as well 
as the molar ratio of the compounds. Therefore, the amount of HOOC-
PEG-PCL was changed. In this study we tested the influence of 2 mg 
HOOC-PEG-PCL, 3 mg and 4 mg on the hydrodynamic diameter of the 
particles. The stirring rate was varied between 350 rpm and 750 rpm 
for variable times. The ultra-sonication time was varied between 75 s 
and 120 s.
Cytotoxicity tests
A549 cells were seeded at a density of 1 × 103 cells per cm2 in a 96 well 
plate and cultivated to confluency. Consequently, they were incu-
bated with drug-loaded and aptamer-functionalized NPs. As negative 
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controls drug-loaded NPs without aptamer modification and NPs 
without any drug loading and functionalization were used. After 
24 h incubation cells were stained with calcein-acetoxymethyl (AM)/
propidium iodide. This staining provides information about the 
ratio of dead and living cells. The non-fluorescent ester calcein-AM 
penetrates the cell membrane and is split by metabolic active cells. 
Calcein forms green fluorescent chelate complexes with iron ions 
thereby only staining living cells. In contrast, propidium iodide can-
not penetrate membranes of living cells and only penetrates mem-
branes of dead cells.
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